Amodiaquin (Camoquin) in the Treatment of Chronic Discoid Lupus Erythematosus

Publisher Website
Google Scholar
Abstract
Amodiaquin (Camoquin), first synthesized in 1946 by Burckhalter and associates,1is one of the 4-aminoquinolines, a group of compounds discovered after the development of quinacrine (Atabrine). Extensive investigations in the period 1946 to 1954 with these compounds, particularly chloraquine and amodiaquin, firmly established their value in the suppressive treatment of vivax and falciparum malaria.2The value of chloroquine and quinacrine in the treatment of discoid lupus erythematosus is well established and need not be reviewed. Having almost simultaneously encountered two patients with chronic discoid lupus erythematosus who failed to respond to quinacrine and chloroquine therapy, we decided to try amodiaquin, since a small supply was available to one of us (R. B. P.) through a local pharmacy. The results in these and in subsequent patients were very gratifying, thus prompting this preliminary report. Report of Cases Case1.—A 31-year-old white woman was

This publication has 0 references indexed in Scilit: